Evidence map›Paper›PMID 42316187›Full record

ArticleJournal of translational medicine2026

S-propargyl-cysteine remodels the HCC microenvironment and potentiates anti-PD-1 therapy through CSE/H

Yuxin Liang, Deyuan Zhong, Hongtao Yan, Yuhao Su, Yahui Chen, Ming Wang, Yizhun Zhu, Qinyan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuxin Liang *Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Deyuan Zhong *Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Hongtao Yan *Liver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Yuhao SuLiver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Yahui ChenLiver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Ming WangLiver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China.
Yizhun ZhuSchool of Pharmacy, Laboratory of Drug Discovery from Natural Resources and Industrialization, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, SAR, 999078, China. yzzhu@must.edu.mo.
Qinyan YangLiver Transplantation Center and HBP Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan Province, 610041, China. lizayangyang@hotmail.com.

Funding

Research Project of Science and Technology Department of Sichuan Province 2024YFHZ0358
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is characterized by aberrant angiogenesis and an immunosuppressive tumor microenvironment, both of which limit durable responses to PD-1 blockade. Strategies that concurrently target vascular dysfunction and immune inhibition may improve therapeutic efficacy.

methodsThe interaction between S-propargyl-cysteine (SPRC) and cystathionine-gamma-lyase (CSE) was assessed by surface plasmon resonance. In human umbilical vein endothelial cells, NF-κB p65 and STAT3 phosphorylation, VEGFA expression, extracellular H

resultsSPRC bound recombinant CSE with nanomolar affinity and enhanced CSE-dependent H

conclusionsSPRC activates a functional CSE/H

Indexed as

Carcinoma, HepatocellularCystathionine gamma-LyaseCysteineHydrogen SulfideLiver NeoplasmsTumor MicroenvironmentAnimalsHep G2 CellsHumansHuman Umbilical Vein Endothelial CellsMiceNeovascularization, PathologicNF-kappa BSTAT3 Transcription FactorVascular Endothelial Growth Factor ACystathionine gamma-LyaseCysteineHydrogen SulfideNF-kappa BSTAT3 Transcription FactorVascular Endothelial Growth Factor AHCCHydrogen sulfide donorLC-MS metabolomicsSPRCTumor microenvironment

Identifiers

PMID42316187
PMCPMC13528017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.